DK2352509T3 - Hla-g-proteiner og farmaceutiske anvendelser deraf - Google Patents

Hla-g-proteiner og farmaceutiske anvendelser deraf

Info

Publication number
DK2352509T3
DK2352509T3 DK09747827.5T DK09747827T DK2352509T3 DK 2352509 T3 DK2352509 T3 DK 2352509T3 DK 09747827 T DK09747827 T DK 09747827T DK 2352509 T3 DK2352509 T3 DK 2352509T3
Authority
DK
Denmark
Prior art keywords
hla
proteins
pharmaceutical applications
pharmaceutical
applications
Prior art date
Application number
DK09747827.5T
Other languages
Danish (da)
English (en)
Inventor
Benoit Favier
Edgardo D Carosella
Joel Lemaoult
Original Assignee
Hla G Technologies
Commissariat Energie Atomique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hla G Technologies, Commissariat Energie Atomique filed Critical Hla G Technologies
Application granted granted Critical
Publication of DK2352509T3 publication Critical patent/DK2352509T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
DK09747827.5T 2008-11-07 2009-11-04 Hla-g-proteiner og farmaceutiske anvendelser deraf DK2352509T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08168675A EP2184070A1 (en) 2008-11-07 2008-11-07 HLA-G proteins and pharmaceutical uses thereof
US11280408P 2008-11-10 2008-11-10
PCT/EP2009/064575 WO2010052228A1 (en) 2008-11-07 2009-11-04 Hla-g proteins and pharmaceutical uses thereof

Publications (1)

Publication Number Publication Date
DK2352509T3 true DK2352509T3 (da) 2013-08-12

Family

ID=40673439

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09747827.5T DK2352509T3 (da) 2008-11-07 2009-11-04 Hla-g-proteiner og farmaceutiske anvendelser deraf

Country Status (8)

Country Link
US (1) US20110268737A1 (cg-RX-API-DMAC7.html)
EP (2) EP2184070A1 (cg-RX-API-DMAC7.html)
JP (1) JP2012507994A (cg-RX-API-DMAC7.html)
CA (1) CA2742517A1 (cg-RX-API-DMAC7.html)
DK (1) DK2352509T3 (cg-RX-API-DMAC7.html)
ES (1) ES2423993T3 (cg-RX-API-DMAC7.html)
PT (1) PT2352509E (cg-RX-API-DMAC7.html)
WO (1) WO2010052228A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2765801A1 (en) * 2009-06-18 2010-12-23 Hla-G Technologies Hla-g alpha 1 multimers and pharmaceutical uses thereof
ES2546509T3 (es) * 2009-06-25 2015-09-24 Commissariat à l'énergie atomique et aux énergies alternatives Polipéptidos multiméricos de HLA-G que incluyen monómeros alfa1-alfa3 y usos farmacéuticos de los mismos
CA2863329C (en) 2012-01-12 2023-01-03 Biogen Idec Ma Inc. Methods of reducing immunogenicity against factor viii in individuals undergoing factor viii therapy
BR112015002091A2 (pt) 2012-08-02 2017-12-12 Hoffmann La Roche método para a produção de um polipeptídeo, polipeptídeo, uso de um polipeptídeo e composição
JP2016500255A (ja) 2012-12-11 2016-01-12 アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ ハイスループットなレセプター：リガンド同定の方法
KR102488477B1 (ko) * 2014-01-21 2023-01-13 앨버트 아인슈타인 컬리지 오브 메디신 신속하고 포괄적인 t-세포 면역 모니터링을 위한 세포 플랫폼
JP6416480B2 (ja) * 2014-01-29 2018-10-31 国立大学法人北海道大学 関節リウマチまたはその関連疾患の予防または治療剤
US9765330B1 (en) 2015-01-09 2017-09-19 Nant Holdings Ip, Llc Compositions and methods for reduction of allograft recognition and rejection
US11505591B2 (en) 2016-05-18 2022-11-22 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
KR20190044029A (ko) 2016-05-18 2019-04-29 알버트 아인슈타인 컬리지 오브 메디슨, 인크. 변이체 pd-l1 폴리펩타이드, t-세포 조절 다량체 폴리펩타이드 및 이들의 사용 방법
MX2018014979A (es) 2016-06-03 2019-10-14 Invectys Anticuerpos específicos dirigidos contra hla-g.
AU2017285224B2 (en) * 2016-06-14 2023-05-18 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
KR20190091292A (ko) 2016-12-02 2019-08-05 바이오버라티브 테라퓨틱스 인크. 응고 인자에 대한 면역 내성 유도 방법
DK3558339T5 (da) 2016-12-22 2024-09-02 Cue Biopharma Inc T-celle-modulerende multimere polypeptider og fremgangsmåder til anvendelse deraf
EP3565829A4 (en) 2017-01-09 2021-01-27 Cue Biopharma, Inc. T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF
US20200010528A1 (en) 2017-03-15 2020-01-09 Cue Biopharma, Inc. Methods for modulating an immune response
CN111886241A (zh) 2018-01-09 2020-11-03 库尔生物制药有限公司 多聚体t细胞调节多肽及其使用方法
JP2021080171A (ja) * 2018-03-13 2021-05-27 国立大学法人北海道大学 改変タンパク質、医薬品、炎症性疾患の予防又は治療剤及び改変タンパク質の製造方法
IL296209A (en) 2020-05-12 2022-11-01 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of using them
EP4211149A4 (en) 2020-09-09 2024-10-09 Cue Biopharma, Inc. MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2717498B1 (fr) 1994-03-18 1996-05-03 Commissariat Energie Atomique Transcrits du gène de CMH de classe I HLA-G et leurs applications.
CA2321222A1 (fr) 1998-02-20 1999-08-26 Commissariat A L'energie Atomique Methode de selection de tumeurs exprimant hla-g, sensibles a un traitement anticancereux et ses applications
FR2794977B1 (fr) 1999-06-18 2003-10-31 Commissariat Energie Atomique Utilisation de compositions contenant des formes solubles d'hla-g dans le traitement de pathologies inflammatoires de la peau, et leur procede d'obtention
FR2810047B1 (fr) 2000-06-13 2004-04-02 Commissariat Energie Atomique Nouvelle isoforme d'hla-g et ses applications
BRPI0417916A (pt) * 2003-12-31 2007-04-10 Merck Patent Gmbh proteìna de fusão de fc-eritropoietina com farmacocinética melhorada
EP1755645A2 (en) * 2004-06-18 2007-02-28 Regeneron Pharmaceuticals, Inc. Vegf inhibitors for the treatment of malignant pleural effusion
WO2007011044A1 (ja) 2005-07-15 2007-01-25 Kyushu University, National University Corporation ジスルフィド結合型hla-g二量体を含む医薬組成物及びジスルフィド結合型hla-g二量体の製造方法
WO2007091078A2 (en) 2006-02-10 2007-08-16 Axordia Limited Polypeptide conjugate comprising hla-g and uses thereof, stem cells transfected with hla-g
CA2652570A1 (en) * 2006-05-15 2007-11-22 Viral Logic Systems Technology Corp. Cd47 related compositions and methods for treating immunological diseases and disorders

Also Published As

Publication number Publication date
EP2352509A1 (en) 2011-08-10
EP2352509B1 (en) 2013-05-15
EP2184070A1 (en) 2010-05-12
JP2012507994A (ja) 2012-04-05
PT2352509E (pt) 2013-08-27
WO2010052228A1 (en) 2010-05-14
ES2423993T3 (es) 2013-09-26
CA2742517A1 (en) 2010-05-14
US20110268737A1 (en) 2011-11-03

Similar Documents

Publication Publication Date Title
DK2352509T3 (da) Hla-g-proteiner og farmaceutiske anvendelser deraf
DK2913344T3 (da) Specifikke bindingsproteiner og anvendelser deraf
DK2209806T3 (da) Anti-hepcidin-antistoffer og anvendelser deraf
DK3339323T3 (da) Anti-n3pglu-amyloid-beta-peptid-antistoffer og anvendelser deraf
DK3292874T3 (da) Anti-mesothelin-immunkonjugater og anvendelser deraf
DK2281006T3 (da) Tværbindingsmidler og anvendelser deraf
DK2118140T3 (da) Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf
DK2605789T3 (da) Modificerede relaxinpolypeptider og anvendelser deraf
DK2328931T3 (da) Selektive anti-hepcidin-25-antistoffer og anvendelser deraf
DK2068887T3 (da) SP35-antistoffer og anvendelser heraf
DK2552434T3 (da) Peptider og anvendelse deraf
DK2059535T3 (da) Prlr-specifikt antistof og anvendelser deraf
DK2648742T3 (da) Formuleringer indeholdende saponiner og anvendelser deraf
DK2139490T3 (da) Diazo-bicykliske smac-mimetiske stoffer og anvendelser deraf
DK2012773T3 (da) Lægemidler og anvendelser deraf
DK2170287T3 (da) Mikropartikler omfattende PCL og anvendelser deraf
DK2544719T3 (da) Cd37-bindingsmolekyler og immunkonjugater deraf
DK2479174T3 (da) 6-aminoquinazolin- eller 3-cyanquinolinderivater, fremstillingsfremgangsmåder og farmaceutiske anvendelser deraf
PL2942355T3 (pl) Nie-hemolityczne białka fuzyjne llo i ich zastosowanie
DK3338790T3 (da) Oligopeptid-forbindelser og anvendelser deraf
DK3067064T3 (da) Modificerede rsv-f-proteiner og fremgangsmåder til anvendelse deraf
DK2240203T3 (da) Alfa5-beta1-antistoffer og deres anvendelser
DK2170827T3 (da) Indolin-2-oner og aza-indolin-2-oner
DK2624866T3 (da) Tumorspecifikke antistoffer og anvendelser deraf
DK3091034T3 (da) Anti-CD40-antistoffer og anvendelser deraf